News | Mammography | January 14, 2021

Inpatient Mammograms Can Reduce Disparities in Breast Cancer Screening Rates

A targeted intervention providing mammograms to hospitalized Medicaid patients can help patients complete overdue breast cancer screening

A targeted intervention providing mammograms to hospitalized Medicaid patients can help patients complete overdue breast cancer screening

Getty Images

January 14, 2021 — Completing cancer screening tests, such as mammograms, can be challenging for low-income people, who may face such challenges as lack of transportation or inability to take time off work. A team at Massachusetts General Hospital (MGH) explored the possibility of addressing preventive care needs when patients are admitted to the hospital.

The pilot study, published in the Annals of Family Medicine, examined the feasibility of performing mammograms in women insured by Medicaid or both Medicaid and Medicare (dual-eligible patients) while they were hospitalized. "We designed the study to reach the patients who face significant barriers to completing their mammograms in the outpatient setting," said Andrew S. Hwang, M.D., M.Ph., an internist at MGH and first author of the study. "National and local data show that Medicaid and dual-eligible patients have low rates of breast cancer screening. This targeted strategy has the potential to reduce disparities in cancer screening rates by addressing patients' acute medical needs and their preventive care needs simultaneously."

Hwang and his colleagues identified Medicaid and dual-eligible patients who were admitted to MGH's General Medicine service and were overdue for mammograms. The women had primary care physicians affiliated with MGH who would be responsible for following up on abnormal mammogram results in collaboration with the MGH Breast Evaluation Team.

Of the 21 women who were identified as appropriate candidates for an inpatient mammogram, 17 women, who were an average age of 59, successfully completed the mammogram. The other four patients were discharged from the hospital before the mammograms could be coordinated. Of the 17 women who completed an inpatient mammogram, 35% had never had a mammogram and the other women were overdue for their mammograms by four years on average. All the mammograms were negative, except one, which was inconclusive, and additional imaging evaluation was recommended to rule out cancer. Completing a mammogram did not increase the patients' hospital length of stay.

Hwang and his colleagues hope to build on the pilot study by offering inpatient mammograms to Medicaid and dual-eligible patients admitted to other areas of the hospital. They also envision potentially delivering additional preventive care services, such as fecal immunochemical tests for colorectal cancer screening, to low-income hospitalized men and women.

"The patients who participated in our pilot study faced significant psychosocial challenges to completing outpatient prevention tests," said Hwang. "Attaining equitable health outcomes for all patients will require innovative solutions that lower the barriers to care by addressing patients' psychosocial needs. In addition, as our health care system transitions from fee-for-service to value-based payment models, improving health outcomes among underserved patient populations will become increasingly important. Completing preventive screening tests, such as mammograms, during hospitalizations can be one way to help patients who might otherwise miss preventive care."

For more information: www.massgeneral.org

Related Content

A comparison of standard mammography imaging (left) in a woman with dense breasts and a breast MRI imaging study (right) showing a clearly defined cancer and is extremely hard to detect on the mammograms.

A comparison of standard mammography imaging (left) in a woman with dense breasts and a breast MRI imaging study (right) showing a clearly defined cancer and is extremely hard to detect on the mammograms. Images from Christiane Kuhl, M.D.

Feature | MRI Breast | March 04, 2021 | By Dave Fornell, Editor
Dense breast tissue can hide cancers i
Researchers said women who skip even one scheduled mammography screening before a breast cancer diagnosis face a significantly higher risk of dying from the cancer.

Getty Images

News | Mammography | March 03, 2021
March 3, 2021 — Attendance at regular ...
55-year-old woman who underwent screening mammogram and ultrasound 7 days after first COVID-19 vaccination dose. Screening mammogram and US demonstrated unilateral left axillary lymph node with cortical thickness of 5 mm on ultrasound (not shown). BI-RADS category 0 was assigned. Ultrasound from diagnostic work-up performed 7 days later showed no change in lymph node size. BI-RADS 3 was assigned. #COVIDvaccine #COVID19

55-year-old woman who underwent screening mammogram and ultrasound 7 days after first COVID-19 vaccination dose. Screening mammogram and US demonstrated unilateral left axillary lymph node with cortical thickness of 5 mm on ultrasound (not shown). BI-RADS category 0 was assigned. Ultrasound from diagnostic work-up performed 7 days later showed no change in lymph node size. BI-RADS 3 was assigned.

News | Breast Imaging | February 24, 2021
F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.

F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.

News | Molecular Imaging | February 22, 2021
February 22, 2021 — Molecular imaging
Examples of the imaging performance of XPCI-CT (b,e) compared to conventional specimen radiography (a,d) and benchmarked against histopathology (c,f). he top row focuses on the similarity between the XPCI-CT slice in (b) and the histological slice in (c). Arrow 1 indicates margin involvement, arrow 2 a variation in density in the internal structure of the tumour mass, arrow 3 tumour-induced inflammation. All this is confirmed by the histological slice in (c), and hardly visible in the conventional image in

Examples of the imaging performance of XPCI-CT (b,e) compared to conventional specimen radiography (a,d) and benchmarked against histopathology (c,f). he top row focuses on the similarity between the XPCI-CT slice in (b) and the histological slice in (c). Arrow 1 indicates margin involvement, arrow 2 a variation in density in the internal structure of the tumour mass, arrow 3 tumour-induced inflammation. All this is confirmed by the histological slice in (c), and hardly visible in the conventional image in (a). The bottom row focuses on the detection of small calcifications, a key feature in DCIS. These are undetectable in (d), detected in (e), enhanced in the maximum intensity projection (MIP) image at the bottom of (f), and confirmed by histopathology in the top part of (f). The scale bar [shown in (b) and (e)] is the same for all images apart from (f), which has its own scale. Red arrows in (e) and (f) indicate the microcalcifications. Image courtesy of Professor Alessandro Olivo

News | Breast Imaging | February 22, 2021
February 22, 2021 — A new X-ray imaging scanne
Screening strategy based on baseline breast density at age 40 may be effective and cost-effective for reducing breast cancer mortality

Getty Images

News | Breast Density | February 10, 2021
February 10, 2021 — A mammography screenin...
Comparison of breast cancer mortality rates (red squares) and distant-stage breast cancer incidence rates from SEER9 (blue dots) and SEER18 (green dots) per 100,000 for white women aged, A, 20–39, B, 40–69, and, C, 70–79 years (3,7,8).

Comparison of breast cancer mortality rates (red squares) and distant-stage breast cancer incidence rates from SEER9 (blue dots) and SEER18 (green dots) per 100,000 for white women aged, A, 20–39, B, 40–69, and, C, 70–79 years (3,7,8). Image courtesy of Radiology 

News | Breast Imaging | February 10, 2021
February 10, 2021 — Breast cancer death rates have stopped declining for women in the U.S.
After acquiring the molecular breast imaging (MBI) assets from GE Healthcare and Dilon Technologies, Inc., SmartBreast Corporation (SmartBreast), a privately held company focused on breast cancer screening and diagnosis, announced today that it has formed a partnership with FoxSemicon Integrated Technologies, Inc. (FITI) to manufacture molecular breast imaging (MBI) systems.
News | Breast Imaging | February 09, 2021
February 9, 2021 — After acquiring the...

Chart courtesy of the American Cancer Society

News | Breast Imaging | February 08, 2021
February 8, 2021 — Cancer ranks as a leading cause of death in every country in the world, and, for the first time,